Publicaciones científicas

Long-term results after resection for soft tissue sarcoma pulmonary metastases

Carlos E. García Franco (a), Salvador Martín Algarra (b), Akiko Tamura Ezcurra (a), Francisco Guillén-Grima (c) , Mikel San-Julián (d), Javier Pardo Mindán (e) and Wenceslao Torre Buxalleu (a)
(a) Department of General Thoracic Surgery, Clinica Universidad Navarra, Avenida Pio XII 36, Pamplona 31008, Spain
(b) Department of Medical Oncology, Clinica Universidad Navarra, Pamplona, Spain
(c) Department of Preventive Medicine, Clinica Universidad Navarra, Pamplona, Spain
(d) Department of Orthopedic Surgery, Clinica Universidad Navarra, Pamplona, Spain
(e) Department of Pathology, Clinica Universidad Navarra, Pamplona, Spain

Revista: Interactive CardioVascular Thoracic Surgery

Fecha: 01-ago-2009

Oncología Médica Medicina Preventiva Cirugía Torácica Cirugía Ortopédica y Traumatología Anatomía Patológica

Isolated pulmonary metastases from soft tissue sarcomas (STS) occur in approximately 20% of the cases. Chemotherapy and surgical resection are the current standard treatment options for these patients. Our goal was to identify any prognostic factors for these patients as well as to estimate their long-term survival rate.

We examined a series of twenty-two consecutive patients with pulmonary metastases from STS, treated in our institution from 1996 to 2006. Univariate (log-rank and Cox-regression) analysis was performed to identify any significant prognostic factor. Five-year survival rates were estimated by using Kaplan–Meier methods. Four patients (18.2%) were alive without any disease, twelve patients (54.5%) died of disease and we lost all track of six patients (27.3%). Follow-up period ranged from 7 to 75 months. Median follow-up: 14 months, median survival: 19 months. Disease-free interval (DFI) (P=0.005), number of lung nodules (P=0.04) and histology type (P=0.01) were significant prognostic factors at univariate analysis.

The overall five-year survival rate was 23.1%. DFI, number of lung nodules at surgery and metastatic histology are significant prognostic factors for patients with resected pulmonary metastases from STS.

CITA DEL ARTÍCULO Interact Cardiovasc Thorac Surg. 2009 Aug;9(2):223-6

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra